A prospective, open-label, non-interventional phase IV study to investigate the COgnitive status, MOod, fatigue and quality of life in relapsing remitting multiple sclerosis patients treated with teriflunomide (Aubagio®) in Daily routine Observational Setting.
Latest Information Update: 09 Sep 2016
At a glance
- Drugs Teriflunomide (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms COMODO trial
- 09 Sep 2016 New trial record